At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PALI Palisade Bio Inc.
Market Closed 12-12 16:00:00 EST
1.94
-0.26
-11.82%
盘后1.96
+0.02+1.04%
19:43 EST
High2.21Low1.93Vol4.55M
Open2.20D1 Closing2.20Amplitude12.73%
Mkt Cap289.06MTradable Cap203.70MTotal Shares149.00M
T/O9.26MT/O Rate4.34%Tradable Shares105.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

BRIEF-Palisade Bio Strengthens Clinical Leadership Team With Appointment Of James Izanec
Reuters  ·  12-02
BRIEF-Palisade Bio Strengthens Clinical Leadership Team With Appointment Of James Izanec
Palisade Bio Strengthens Clinical Leadership Team With Appointment of James Izanec, Md, Agaf as Vice President, Clinical Development
THOMSON REUTERS  ·  12-02
Palisade Bio Strengthens Clinical Leadership Team With Appointment of James Izanec, Md, Agaf as Vice President, Clinical Development
Palisade Bio price target raised to $8 from $2 at Maxim
TIPRANKS  ·  11-12
Palisade Bio price target raised to $8 from $2 at Maxim
Palisade Bio Inc expected to post a loss of 27 cents a share - Earnings Preview
Reuters  ·  11-07
Palisade Bio Inc expected to post a loss of 27 cents a share - Earnings Preview
Palisade Bio Inc. Announces Date for Upcoming Special Stockholders Meeting
Reuters  ·  10-29
Palisade Bio Inc. Announces Date for Upcoming Special Stockholders Meeting
BRIEF-Palisade Bio Appoints Sharon Skare As Vice President, Global Head Of Clinical Operations
Reuters  ·  10-28
BRIEF-Palisade Bio Appoints Sharon Skare As Vice President, Global Head Of Clinical Operations
Palisade Bio Inc. held annual shareholder meeting
Reuters  ·  10-21
Palisade Bio Inc. held annual shareholder meeting
Palisade Bio Inc. Announces Date for Upcoming Special Stockholders Meeting
Reuters  ·  10-20
Palisade Bio Inc. Announces Date for Upcoming Special Stockholders Meeting
BRIEF-Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn’s Disease (FSCD)
Reuters  ·  10-20
BRIEF-Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn’s Disease (FSCD)
Palisade Bio Inc - Data to Support Phase 2 Ind Submissions to FDA in H1 2026
THOMSON REUTERS  ·  10-20
Palisade Bio Inc - Data to Support Phase 2 Ind Submissions to FDA in H1 2026
Palisade Bio Inc - Topline Data for Pali-2108 Study Expected in Q1 2026
THOMSON REUTERS  ·  10-20
Palisade Bio Inc - Topline Data for Pali-2108 Study Expected in Q1 2026
Palisade Bio Announces First Patients Dosed in Phase 1B Study of Oral First-in-Class Pde4 Inhibitor Prodrug, Pali-2108, for the Treatment of Fibrostenotic Crohn’s Disease (Fscd)
THOMSON REUTERS  ·  10-20
Palisade Bio Announces First Patients Dosed in Phase 1B Study of Oral First-in-Class Pde4 Inhibitor Prodrug, Pali-2108, for the Treatment of Fibrostenotic Crohn’s Disease (Fscd)
Palisade Bio granted Canadian patent covering PALI-2108 composition
TIPRANKS  ·  10-13
Palisade Bio granted Canadian patent covering PALI-2108 composition
Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108
GlobeNewswire  ·  10-13
Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108
Steven Cohen Doubles The S&P 500 — And His Next Bet's All Gut
Benzinga_recent_news  ·  10-08
Steven Cohen Doubles The S&P 500 — And His Next Bet's All Gut
Palisade Bio Closes $138 Million Public Offering
MT Newswires Live  ·  10-03
Palisade Bio Closes $138 Million Public Offering
Palisade Bio Prices Upsized $120 Million Underwritten Public Offering; Shares Rise
MT Newswires Live  ·  10-01
Palisade Bio Prices Upsized $120 Million Underwritten Public Offering; Shares Rise
Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock
THOMSON REUTERS  ·  10-01
Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock
BRIEF-Palisade Bio Announces Adjournment Of Special Meeting Of Stockholders Due To Lack Of Quorum
Reuters  ·  09-27
BRIEF-Palisade Bio Announces Adjournment Of Special Meeting Of Stockholders Due To Lack Of Quorum
Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum
THOMSON REUTERS  ·  09-27
Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum

Introduction

Company Name.
Palisade Bio Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid to reduce the formation of postoperative adhesions, postoperative ileus, and return of bowel function in adults. It has a license agreement with the Regents of the University of California; and co-development and distribution agreement with Newsoara Biopharma Co., Ltd. Palisade Bio, Inc. is based in Carlsbad, California.
Issue price:
--